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Abstract
 
The strongest susceptibility genes for the development of systemic lupus erythematosus (SLE)
in humans are null mutants of classical pathway complement proteins. There is a hierarchy of
disease susceptibility and severity according to the position of the missing protein in the activa-
tion pathway, with the severest disease associated with C1q deficiency. Here we demonstrate,
using novel in vivo models of apoptotic cell clearance during sterile peritonitis, a similar hierar-
chical role for classical pathway complement proteins in vivo in the clearance of apoptotic cells
by macrophages. Our results constitute the first demonstration of an impairment in the phago-
cytosis of apoptotic cells by macrophages in vivo in a mammalian system. Apoptotic cells are
thought to be a major source of the autoantigens of SLE, and impairment of their removal by
complement may explain the link between hereditary complement deficiency and the develop-
ment of SLE.
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Introduction
 
Inherited deficiencies of the early components of the classi-
cal pathway of complement, particularly C1q and C4, are
the strongest disease susceptibility genes for the develop-
 
ment of systemic lupus erythematosus (SLE)
 
1
 
 that have
been identified in humans (1). In addition, gene-targeted
 
C1q-deficient (
 
C1qa
 
2
 
/
 
2
 
) mice also develop a lupus-like
disease characterized by antinuclear autoantibodies and
proliferative glomerulonephritis (2). These observations
show that there is an activity of the early components of
the classical pathway that protects from the development of
SLE. It is an important challenge to understand the mecha-
nism of this protection.
C1q has been shown to bind specifically to the surface
blebs of apoptotic keratinocytes (3). This finding, together
with the observation that the common autoantigens tar-
geted in SLE are localized in high concentrations on the
surfaces of apoptotic cells (4), has led to the hypothesis that
C1q deficiency may predispose to autoimmunity as a con-
sequence of an impaired clearance of apoptotic cells (2, 3).
Immunization of mice with apoptotic thymocytes can in-
duce the production of autoantibodies (5), supporting the
hypothesis that apoptotic cells may provide a source of au-
toantigens. In mice deficient in C1q, we have observed an
increased number of glomerular apoptotic bodies in the ab-
sence of histological evidence of glomerulonephritis and
independently from C3 activation, supporting the hypoth-
esis that C1q may be involved in the clearance of apoptotic
cells (2, 6).
Here we have used complement-deficient mice to deter-
mine the relative contribution of different complement
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proteins to the phagocytosis of apoptotic cells by both in-
flammatory and resident murine macrophages using novel
in vivo peritoneal models of apoptotic cell clearance. We
have also studied the uptake of apoptotic cells in vitro by
macrophages from C1q-deficient humans. We report the
first demonstration of an in vivo apoptotic cell clearance
defect in a mammalian system that correlates closely with
predisposition to the spontaneous development of SLE.
 
Materials and Methods
 
Mice. C1qa
 
2
 
/
 
2 
 
mice were generated as previously described
(2) and were studied on the mixed (129/Sv 
 
3
 
 C57BL/6) and
pure inbred 129/Sv and C57BL/6 (backcrossed for seven genera-
tions) genetic backgrounds as specified when appropriate. C4-
deficient (
 
C4
 
2
 
/
 
2
 
) and C3-deficient (
 
C3
 
2
 
/
 
2
 
) mice used were on
the mixed (129/Sv 
 
3
 
 C57BL/6) genetic background (7, 8). All
experiments described were conducted on mice matched for age
(8–12 wk), strain, and sex. All animal work was conducted in ac-
cordance with institutional guidelines.
 
Apoptotic Cells.
 
Apoptosis was induced in the human Jurkat
T cell line by exposure to UVB
 
312nm
 
 (equivalent to 800 mJ/cm
 
2
 
),
followed by 2-h culture in RPMI 1640/0.4% BSA. This resulted
in a population of cells that was 
 
z
 
70% apoptotic and 
 
.
 
95%
“viable.” Mouse thymocytes were obtained by mechanical disso-
ciation of thymi from 3–5-wk-old mice and were induced to
undergo apoptosis by 4-h culture in RPMI 1640/10% heat-inacti-
vated FCS in the presence of 1
 
m
 
M dexamethasone (Sigma-Aldrich).
This resulted in a population of cells that was 
 
z
 
50% apoptotic
and 
 
.
 
95% viable. Apoptosis was confirmed by annexin V bind-
ing, TdT-mediated dUTP-biotin nick-end labeling (TUNEL)
staining, and morphological changes including nuclear fragmen-
tation and condensation, loss of cell volume, and membrane
blebbing. Cells were considered viable when they excluded pro-
pidium iodide and trypan blue, and this indicated the presence of
an “early” apoptotic cell population.
 
In Vivo Clearance of Apoptotic Cells by Peritoneal Macrophages.
 
Gene-targeted and control mice were injected intraperitoneally
with 1 ml of sterile 4% thioglycollate to induce sterile peritonitis.
4 d later, the mice were injected intraperitoneally with 10
 
7
 
 apop-
totic Jurkat T cells or 1–3 
 
3 
 
10
 
7
 
 apoptotic murine thymocytes in
a volume of 200 
 
m
 
l. To study phagocytosis by resident peritoneal
macrophages, mice were injected with apoptotic cells without
prior treatment with thioglycollate. In all of the experiments,
unless otherwise stated, the mice were killed after 30 min and
the peritoneal cells were recovered by lavage with 5 ml of ice
cold HBSS/5 mM EDTA. Guided by the results obtained with
the initial kinetic experiments, 30 min was selected as the single
time point for the majority of experiments where more than one
group of complement-deficient mice was studied. Phagocytosis
was scored on coded cytospins of peritoneal cells stained with
Diff-Quik (Dade Behring AG) and was expressed as the percent-
age of macrophages ingesting apoptotic cells or as a phagocytic
index (the number of ingested apoptotic cells per 100 macro-
phages). Apoptotic cells were considered phagocytosed when
 
.
 
50% of the cell volume was contained within the border of the
macrophage, which is believed to underestimate the level of
phagocytosis (9). In all of the experiments, the percentage of mac-
rophages ingesting correlated closely with the phagocytic index
(data not shown). Between 300 and 500 macrophages were
scored in each sample. FACS
 
®
 
 analysis of phagocytic uptake was
performed by fluorescent labeling of the apoptotic cells before
 
injection with 5- (and 6-) carboxytetramethylrhodamine, suc-
cinimidyl ester (5[6]-TAMRA, SE; Molecular Probes) as previ-
ously described (10) and by detecting macrophages after lavage
with FITC-conjugated F4/80 (Caltag). Reconstitution experi-
ments were performed by adding serum to the apoptotic cells
immediately before injection to a final concentration of 20%
vol/vol.
 
In Vitro Phagocytosis Assay.
 
PBMCs were isolated from C1q-
deficient and normal humans and cultured as previously described
(11) on coverslips in 24-well plates. Apoptotic Jurkat T cells (5 
 
3
 
10
 
6
 
 per well) were fed to the monocyte-derived macrophages be-
tween 7 and 10 d after isolation in the presence of 15% autolo-
gous serum for 1 h, and uningested cells were removed by re-
peated washing with PBS. The C1q-deficient serum was
reconstituted with purified human C1q (Sigma-Aldrich) as indi-
cated. Phagocytosis was scored on Diff-Quik–stained coded slides
as described above.
 
Statistics.
 
Statistics were calculated using GraphPad Prism™
(version 2.0; GraphPad Software). Student’s 
 
t
 
 test and one-way
analysis of variance (ANOVA) with Bonferroni multiple compar-
ison test was applied throughout.
 
Results
 
Phagocytosis of Apoptotic Jurkat T Cells during Sterile Perito-
nitis.
 
Complement-deficient and wild-type mice were in-
jected intraperitoneally with apoptotic human Jurkat T
cells 4 d after induction of sterile peritonitis with thiogly-
collate. Phagocytosis of apoptotic Jurkat T cells by elicited
peritoneal macrophages was impaired in C1q-deficient ani-
mals (Fig. 1 A), resulting in a delay in the clearance of the
apoptotic cells from the peritoneum (Fig. 1 B). The defect
in phagocytosis was observed in C1q-deficient animals on
both C57BL/6 and 129/Sv genetic backgrounds (Fig. 1 C).
C1q deficiency did not alter the recruitment of macro-
phages into the peritoneum by thioglycollate. However, the
genetic background of the mice used did have significant
influence over the number of macrophages recruited in re-
sponse to thioglycollate (C57BL/6 
 
. 
 
129/Sv 
 
3
 
 C57BL/6 
 
.
 
129/Sv; Fig. 1 D). Comparison of the phagocytic uptake of
an equivalent number of UV-treated and untreated Jurkat
T cells confirmed that uptake was related to the level of ap-
optosis in the cell population (percentage of macrophages
ingesting UV-treated cells 
 
5 
 
49.1
 
 6 
 
5.7% compared with
11.8
 
 6 
 
1.8% with untreated cells [mean
 
 6 
 
SEM],
 
 n 
 
5 
 
4 in
each group;
 
 P 
 
5 
 
0.0008, Student’s 
 
t
 
 test). FACS
 
®
 
 analysis
of the phagocytosis of 5(6)-TAMRA, SE fluorescently la-
beled apoptotic Jurkat T cells by F4/80
 
1
 
 macrophages cor-
roborated the data obtained by manual counting of coded
cytospin preparations (Fig. 1 E). Inflammatory macro-
phages of C4-deficient mice showed a defect in the phago-
cytic uptake of the apoptotic Jurkat T cells in vivo similar
to that observed in 
 
C1qa
 
2
 
/
 
2
 
 mice (Fig. 1 F), suggesting that
the activation of the classical pathway and probably op-
sonization with C3 or C4 was the most likely mechanism
for the clearance of apoptotic Jurkat T cells.
 
Phagocytosis of Apoptotic Murine Thymocytes during Sterile
Peritonitis.
 
Although the observed phagocytic clearance of
Jurkat T cells was specific for apoptotic cells, the possibility
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Figure 1. Phagocytic clearance of apoptotic Jurkat T cells during sterile peritonitis. Mice were injected intraperitoneally with 107 apoptotic human Jurkat
T cells 4 d after treatment with thioglycollate. (A) Graph showing the percentage of inflammatory macrophages from C57BL/6 mice phagocytosing
apoptotic bodies at different time points after injection. The C1qa2/2 mice (s) showed a significant delay in phagocytic uptake of the apoptotic cells
compared with the wild-type mice (d) (P , 0.01 after 15 and 30 min, Student’s t test; data shown corresponds to mean 6 SEM of three to four mice in
each group). (B) Graph showing the number of uningested apoptotic cells remaining free in the peritoneum of the mice shown in A. The C1qa2/2 ani-
mals had a significant delay in the clearance of the apoptotic cells as a consequence of the impaired phagocytosis (P , 0.05 at the 15 and 60 min time
points, Student’s t test; data shown corresponds to mean 6 SEM). (C) Scatter plots showing the percentage of elicited peritoneal macrophages containing
phagocytosed apoptotic bodies 30 min after intraperitoneal injection of apoptotic Jurkat T cells. C1qa2/2 mice (s) showed a significant reduction in the
phagocytosis of apoptotic bodies compared with C1qa1/1 mice (d) irrespective of the genetic backgrounds of the experimental animals (horizontal bars
denote means; P , 0.005 in each of the three experiments, Student’s t test). (D) Peritoneal recruitment of macrophages in response to thioglycollate in
wild-type (black bars), C1q-deficient (white bars), and C4-deficient (hatched bars) mice. Although neither C1q nor C4 deficiency affected macrophage
recruitment, the number of macrophages elicited by thioglycollate was dependent on the genetic background of the animals used (C57BL/6 . 129/Sv 3
C57BL/6 . 129/Sv). The data shown represents the mean 6 SEM of four to eight mice in each group. (E) FACS® analysis of the phagocytic uptake of
5(6)-TAMRA, SE–labeled apoptotic cells by F4/801 peritoneal macrophages 30 min after the injection of apoptotic cells in C1q-deficient and wild-type
mice (129/Sv 3 C57BL/6). The F4/801, 5(6)-TAMRA, SE1 cells represent macrophages associated with apoptotic cells. Significantly fewer F4/801
cells were associated with the 5(6)-TAMRA, SE1 apoptotic cells in the C1qa2/2 animals. (F) Graph showing the percentage of phagocytosing macro-
phages 30 min after injection of 107 apoptotic Jurkat cells into C1qa2/2, C42/2, and wild-type (wt) 129/Sv 3 C57BL/6 mice during sterile peritonitis.
The phagocytic uptake was significantly different between the three groups (P 5 0.0002, one-way ANOVA). Both C1qa2/2 (s) and C42/2 (h) mice
exhibited significantly impaired phagocytosis compared with the wild-type (d) mice (P , 0.001 and P , 0.01, respectively, Bonferroni multiple com-
parison test). Data shown is representative of three independent experiments. Horizontal bars denote means.
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could not be ruled out that the dependence on comple-
ment in this system was due to the heterologous nature of
the target apoptotic cells. Therefore, the experiments with
the inflammatory macrophages were repeated using apop-
totic murine thymocytes (Fig. 2 A). Irrespective of their
genetic backgrounds, the C1qa2/2 mice exhibited a defect
in phagocytic uptake of apoptotic thymocytes by inflam-
matory macrophages compared with wild-type controls
(129/Sv genetic background: 20.5 6 1.4% in the C1qa2/2
animals compared with 39.8 6 6.9% [mean 6 SEM] in the
controls; P 5 0.024, Student’s t test; C57BL/6 genetic
background: 14.7 6 0.8% in C1qa2/2 mice compared with
19.7 6 0.9% in controls; P 5 0.005, Student’s t test).
However, in contrast to the results obtained with the apop-
totic human Jurkat T cells, phagocytic uptake of apoptotic
thymocytes in the C4-deficient mice was only partially im-
paired compared with the C1qa2/2 mice (Fig. 2 B). These
findings suggest that, although activation of the classical
pathway proteins after the binding of C1q plays a role in
apoptotic cell clearance, C1q has a specific role in its own
right in the clearance of apoptotic cells.
We confirmed that deficiency of C1q was directly re-
sponsible for the impaired phagocytic uptake of apoptotic
cells by performing reconstitution assays in vivo. C1qa2/2
and C1qa1/1 mice were injected intraperitoneally with ap-
optotic cells in the presence of 20% normal or C1q-defi-
cient mouse serum. Injection of apoptotic cells (both Jurkat
T cells and murine thymocytes) in the presence of normal
mouse serum significantly increased the phagocytic uptake
in the C1q-deficient animals (Fig. 2 C) and showed that
the presence of C1q at the time of injection of the apop-
totic cells was a critical factor in their appropriate clearance.
Phagocytosis of Apoptotic Murine Thymocytes by Resident
Peritoneal Macrophages In Vivo. The role of C3 and the al-
Figure 2. Phagocytosis of apoptotic murine thymocytes by inflammatory macrophages. (A) Representative photomicrographs of cytospin preparations
of peritoneal lavage cells from C1q-deficient (top) and wild-type (bottom) mice recovered 30 min after injection with 3 3 107 apoptotic thymocytes, 4 d
after injection of thioglycollate. Arrows indicate apoptotic bodies. (B) Phagocytosis of apoptotic thymocytes by inflammatory macrophages of C1qa2/2
(s), C42/2 (h), and wild-type (wt; d) 129/Sv 3 C57BL/6 mice was significantly different (P , 0.0001, one-way ANOVA). Phagocytosis in the
C1qa2/2 mice was significantly lower than the uptake in the C42/2 and the wild-type mice (P , 0.01 and P , 0.001, respectively, Bonferroni multiple
comparison test); however, the C42/2 mice also exhibited a defect in phagocytosis compared with control mice (P , 0.01, Bonferroni multiple compar-
ison test). Horizontal bars denote means. (C) Reconstitution of C1q-deficient mice with wild-type serum. Apoptotic Jurkat T cells or murine thymocytes
were suspended in a 20% vol/vol solution of C1q-deficient (open symbols) or -sufficient (closed symbols) mouse serum and injected into C1qa2/2 (cir-
cles) and C1qa1/1 (squares) mice as indicated. The phagocytic uptake between the groups was significantly different 30 min after injection (P 5 0.0001 in
both separate experiments, one-way ANOVA). Phagocytosis in the reconstituted C1qa2/2 mice injected with normal mouse serum was significantly
higher than in the C1qa2/2 mice injected with C1q-deficient serum when either Jurkat T cells or thymocytes were used (P , 0.01 in both experiments,
Bonferroni multiple comparison tests). Horizontal bars denote means. Phagocytosis was scored on coded cytospin preparations. Mice used for the recon-
stitution experiments with apoptotic Jurkat cells and apoptotic thymocytes were on the C57BL/6 and 129/Sv genetic backgrounds, respectively.
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ternative pathway of complement in the clearance of apop-
totic cells by inflammatory macrophages could not be as-
sessed in vivo, as mice deficient in the alternative pathway
exhibit an impaired inflammatory response to thioglycollate
characterized by reduced neutrophil and macrophage re-
cruitment (our unpublished data). To address the contribu-
tions of C3 and the alternative pathway of complement to
the clearance of apoptotic murine thymocytes, resident
peritoneal macrophages were studied in C1qa2/2, C42/2,
C32/2, and wild-type mice in vivo. C1qa2/2 mice were
the only animals to exhibit a consistent defect in the phago-
cytosis of apoptotic cells by resident macrophages (Fig. 3),
showing that C1q plays a significant role in the normal
physiological clearance of apoptotic cells in vivo.
Phagocytosis of Apoptotic Jurkat T Cells by Human Mono-
cyte–derived Macrophages. To establish the relevance of our
observations in mice to humans, the role of C1q in the
clearance of apoptotic cells was investigated by measuring
the phagocytosis of apoptotic Jurkat T cells by monocyte-
derived macrophages from three individuals with heredi-
tary C1q deficiency. C1q-deficient macrophages, in the
presence of autologous serum, showed a kinetic defect in
the phagocytic uptake of apoptotic cells in vitro (Fig. 4 A)
similar to that seen in the mice in vivo (Fig. 1 A) and con-
sistent with other recent in vitro experiments using com-
plement-depleted sera (12). Addition of purified human
C1q to the C1q-deficient serum (final concentration of 75
mg/ml) rectified this defect (Fig. 4 A). Furthermore, phago-
cytosis of apoptotic cells by C1q-deficient macrophages
from three different individuals (from two separate families)
was similarly impaired compared with normal controls, and
purified C1q protein corrected this in a dose-dependent
manner (Fig. 4 B). Notably, serum taken from a C1q-defi-
cient patient 30 min after treatment by infusion of 2 U of
fresh frozen plasma (resulting in a serum C1q concentration
of 27 mg/ml) when used in this phagocytosis assay also sig-
nificantly increased the phagocytic uptake of apoptotic cells
compared with autologous serum obtained before infusion
(18.9 6 3.6% before infusion and 74.5 6 4.9% [mean 6
SEM] after treatment with fresh frozen plasma; P 5
0.0026, Student’s t test).
Figure 3. Clearance of apoptotic mouse thymocytes by resident perito-
neal macrophages. The phagocytic uptake by resident peritoneal mac-
rophages 30 min after the intraperitoneal injection of 2 3 107 apoptotic
cells was significantly reduced in C1qa2/2 (s) mice compared with C42/2
(h), C32/2 (e), and wild-type (wt) 129/Sv 3 C57BL/6 (d) control
mice. Data shown represents two pooled representative experiments (P ,
0.01, P , 0.01, and P , 0.001, respectively, Bonferroni multiple com-
parison test; P 5 0.0009, one-way ANOVA). Horizontal bars denote
means. Phagocytosis was scored on coded cytospin preparations. Impaired
phagocytic uptake by the resident macrophages in the C1qa2/2 animals
was observed in three separate experiments (data not shown).
Figure 4. Phagocytosis of apoptotic Jurkat T cells by human monocyte–derived macrophages from three C1q-deficient patients. (A) The phagocytic
uptake of apoptotic cells by C1q-deficient macrophages (s) in vitro showed a kinetic defect when compared with both of the normal controls (d, j) (at
60 min, P , 0.01 in both cases, Bonferroni multiple comparison test; P 5 0.001, one-way ANOVA). When the C1q-deficient serum was reconstituted
with 75 mg/ml of purified C1q (h), the phagocytic uptake was no longer significantly different from the controls. Data shown represents the mean 6
SEM for triplicate samples. (B) C1q-deficient macrophages, from three individual patients, in autologous serum (s) showed a significant reduction in
phagocytosis compared with normal controls (d) after 60-min incubation (P 5 0.0038, Student’s t test). Addition of purified human C1q protein to the
autologous C1q-deficient serum (final concentration of 75 mg/ml in the serum) of one patient rectified the defect in the phagocytic uptake of apoptotic
bodies in a dose-dependent manner. Data shown corresponds to the mean of three to four wells for each individual, and horizontal bars denote means.
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Discussion
The phagocytosis of apoptotic cells is thought to be im-
portant in the resolution of inflammation (13), and multiple
complementary ligand–receptor systems have been identi-
fied in vitro that may facilitate this process (14–23). Re-
cently, complement has also been implicated in the phago-
cytosis of apoptotic cells by the observation that C1q binds
specifically to the surface blebs of apoptotic cells (3) and
that C3 depletion of human serum impairs uptake of apop-
totic cells by human monocyte–derived macrophages in
vitro (12). In this study, we have used complement-defi-
cient mice to determine the relative contribution of differ-
ent complement proteins to the phagocytosis of apoptotic
cells in vivo. Our initial in vivo clearance experiments us-
ing apoptotic Jurkat human T cells indicated that comple-
ment did indeed play a significant role in the phagocytic
clearance of apoptotic cells by inflammatory macrophages
in vivo, consistent with previous observations in an in vitro
human system (12). A significant, and equivalent, delay in
the clearance of apoptotic cells was observed in both C1q-
and C4-deficient mice, indicating that opsonization with
C3 via classical pathway activation was the most likely me-
diator of clearance in this model. However, when apop-
totic murine thymocytes were used instead of apoptotic
human cells, differences were seen in the phagocytic up-
take between inflammatory macrophages from C1q- and
C4-deficient mice. Although the C4-deficient mice exhib-
ited a defect in the phagocytic uptake of apoptotic murine
cells by inflammatory macrophages, this defect was not as
severe as that seen in the C1q-deficient animals. This result
indicated that there is a hierarchy of importance of classical
pathway complement proteins in the phagocytic clearance
of apoptotic cells.
These observations indicated that the clearance of synge-
neic apoptotic cells was dependent on C1q in two ways: an
effect mediated directly by C1q, and a second effect medi-
ated by C1q as an activator of the classical pathway. Clear-
ance of apoptotic cells in vivo was more dependent on the
second mechanism of classical pathway activation when a
heterologous system was used (i.e., when human apoptotic
cells were injected into mice), indicating the importance of
using syngeneic cells in these assays to elucidate the inde-
pendent role of C1q. This difference may be due to a re-
duction in the ability of human compared with mouse
lymphocytes to regulate the activation of mouse comple-
ment or the presence of xenoreactive natural antibodies.
To address the role of C3 in the phagocytosis of apop-
totic cells, resident peritoneal macrophages, as opposed to
inflammatory macrophages induced by thioglycollate, were
studied in vivo. C1q-deficient mice were the only comple-
ment-deficient animals to exhibit a defect in the phagocy-
tosis of apoptotic cells by resident peritoneal macrophages
in vivo, suggesting that C1q is the complement protein
with the predominant role in the physiological phagocyto-
sis of apoptotic cells in vivo in the absence of inflammation.
However, there was a role for C4 in the clearance of apop-
totic syngeneic thymocytes by inflammatory macrophages.
These results imply that C1q and C4 may mediate the up-
take of apoptotic cells by different mechanisms, either in-
volving separate receptors or a single receptor that is only
activated for uptake of C4/C3-coated cells on inflamma-
tory macrophages. The lack of a role for C4 and C3 in the
phagocytosis of apoptotic cells by resident peritoneal mac-
rophages could be related to the activation state of the mac-
rophages, as it is well recognized that murine resident peri-
toneal macrophages are unable to phagocytose C3-coated
particles without additional stimuli, such as thioglycollate
elicitation (24–29). However, these resident macrophages
may be able to utilize C1q as an opsonin, presumably via
direct interaction with one of the candidate C1q receptors
(30–33). In the guinea pig, C1q is bound and degraded by
both resident and thioglycollate-elicited peritoneal mac-
rophages (34). This binding and degradation was increased
by thioglycollate activation and found to be consistent with
an increase in the number of receptors.
Apoptotic cells express on their surface blebs many of the
autoantigens of SLE (4), and they also expose on their cel-
lular membranes the negatively charged phospholipids that
are the ligands of antiphospholipid autoantibodies (9, 35).
In addition, there is evidence that the enzymes specific to
the cell death program may cleave and modify many au-
toantigens of SLE, which may reveal cryptic epitopes (36,
37). These findings suggest that apoptotic cells are a major
source of autoantigens in SLE and that an impairment of
their physiological clearance may promote the develop-
ment of autoimmunity. Indeed, macrophages from humans
with SLE have been shown to exhibit a reduction in the
phagocytic uptake of apoptotic cells in vitro (38). The data
presented here demonstrate for the first time an in vivo de-
ficiency in one of the clearance mechanisms of apoptotic
cells in mammals. The proteins of the complement classical
pathway showed a hierarchy in the clearance of apoptotic
cells with the greatest dependence on the activity of C1q
and with a lesser dependence on C4.
We previously showed the presence of glomerulone-
phritis and an excess of glomerular apoptotic bodies in
C1q-deficient mice and in mice deficient in C1q, C2, and
factor B (2, 6). By contrast, there was no glomerulonephri-
tis or increased number of glomerular apoptotic bodies in
mice with C2 and factor B deficiency alone (6). The obser-
vations presented in this paper suggest that the increased
presence of apoptotic cells in the glomeruli of mice defi-
cient in C1q may be a direct result of impaired clearance of
apoptotic cells in vivo. Furthermore, both sets of findings
taken together indicate that deficiency of C1q, rather than
the entire classical pathway, is the predominant cause of
both the impaired clearance of apoptotic cells and the in-
creased predisposition to spontaneous autoimmunity.
In support of these findings in murine models, C1q-defi-
cient macrophages from three C1q-deficient humans with
SLE showed a defect in the phagocytic uptake of apoptotic
cells in vitro. This defect was corrected, in a dose-depen-
dent manner, using purified C1q protein. Furthermore, ex-
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periments in vitro have shown that culture of human
monocyte–derived macrophages in wells precoated with
purified C1q partially inhibits the phagocytic uptake of ap-
optotic cells (Ogden, C., unpublished data). Collectively,
these findings demonstrate an important role of the early
proteins of the classical pathway in the clearance of apop-
totic cells.
If macrophages fail to clear apoptotic cells normally,
what might be the consequences? A second route for the
uptake of apoptotic cells has been identified that may favor
an autoimmune rather than an antiinflammatory response
to apoptotic cells. Immature dendritic cells can phagocytose
apoptotic cells and present apoptotic cell–derived antigens
to MHC class I– and II-restricted T cells (39–41) in a dose-
dependent manner (42). Furthermore, blockade of mac-
rophage-mediated removal of a syngeneic apoptotic tumor
cell line in vivo in mice led to an augmented CTL response
when the mice were rechallenged with live tumor cells
(43). These observations are consistent with the existence
of a balance in vivo between macrophage- and dendritic
cell–mediated clearance of apoptotic cells. Macrophages
may maintain homeostasis by promoting the silent disposal
of apoptotic cell debris, whereas clearance by dendritic cells
favors an immune response. In C1q-deficient animals, a de-
lay in the clearance of apoptotic cells by macrophages may
tilt this balance toward an autoimmune response.
The establishment of an in vivo model for quantifying
the phagocytosis of apoptotic cells by macrophages may
provide a new approach for testing antiinflammatory thera-
pies directed toward enhancing the resolution of inflamma-
tion by promoting macrophage-mediated removal of apop-
totic cell debris. This model will also allow the mechanisms
and kinetics of the clearance of apoptotic cells to be studied
in mice with gene targeted mutations of other candidate
molecules involved in apoptotic clearance pathways.
In conclusion, the findings of this study may help to re-
solve the association between hereditary complement defi-
ciency and the development of SLE. The hierarchy of both
the prevalence and severity of SLE according to the posi-
tion of the missing protein in the classical pathway was par-
alleled by a similar hierarchy of the activity of classical path-
way complement proteins in the clearance of apoptotic
cells.
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